Pioneering the path to Digital Therapeutics through Real World Evidence, Outcomes and Analytics.
"Digital therapeutics (DTx) (n) - deliver evidence-based therapeutic interventions to patients that are driven by high quality software programs to prevent, manage, or treat a broad spectrum of physical, mental, and behavioral conditions. Digital therapeutics form an independent category of evidence-based products within the broader digital health landscape, and are distinct from pure-play adherence, diagnostic, and telehealth products." -- Digital Therapeutics Alliance
"Digital Therapeutics (DTx) delivers evidence-based therapeutic interventions to patients that are driven by high-quality software programs to prevent, manage, or treat a broad spectrum of physical, mental, and behavioral conditions. Digital therapeutics form an independent category of evidence-based products within the broader digital health landscape, and are distinct from pure-play adherence, diagnostic, and telehealth products."
Digital Therapeutics Alliance
About ApexB.io
Discover Our Expertise
At ApexB.io, we are a team of Clinicians, Software Engineers, Pharma Researchers, Data Scientists, Digital Experts, Game Designers, and Regulatory experts collaborating together to design the next frontier in medicine.
ApexB.io has built a pipeline of Digital Therapeutics products, which improves patients' lives by changing their behaviors by increasing engagement and by motivating them in fun, rewarding ways.
ApexBio partners with BioTechs, Universities, Providers, Payers/ACOs and Health Systems to bring innovative products to market and create value in the entire healthcare ecosystem.
Substance Abuse
Alcoholism and Opiod Addiction
Apexbio has partnered with Universities in US and Canada and BioTech companies to build Digital Therapeutics for Alcoholism and Opioid Addiction.
Mental Health
Scizophrenia and Depression
ApexB.io has partnered with Biotech companies to develop Digital Therapeutic products who work in conjunction with pharmaceutical products and independent of pharmaceutical products.
Cardio-Metabolic Disorders
Diabetes and NASH
Apexbio is in late stage discussions with BioTech partners to launch Phase 4 trials and DTx products for NASH and Diabetes Type I and Type 2 conditions.